Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2011

View Archived Issues

FDA approves Oxford BioMedica's IND for UshStat trial

Exparel leads to sustained release of bupivacaine

Lilly begins phase II study of LY-2510924 in SCLC

New carbazole-linked hybrid antitumor agents prepared

Servier and Miragen enter research partnership for microRNA-targeted drugs

BeiGene in-licenses two clinical-stage oncology candidates

Ampio Pharmaceuticals reports clinical data on intranasal danazol

AstraZeneca and Forest Laboratories advance antibiotic combination CAZ-AVI

Vandetanib/bicalutamide combination trial does not meet primary endpoint

Phase II study assessed combination therapy containing rilotumumab in cancer

Korean scientists identify serum biomarkers of preeclampsia

Brazilian university designs new analgesic with in vivo activity

Clinical data analyses examine efficacy and safety of lorcaserin

Scientists at Prosidion prepare new ghrelin receptor ligands

Wisconsin Alumni Research Foundation patents new ligands of vitamin D receptor

Novel agents for HCV infection disclosed by Vertex

New protein kinase inhibitors presented by GSK

Abbott to split into two companies

Vertex submits Kalydeco NDA for priority review

Viralytics begins enrollment in phase II Cavatak trial following approval for dosing

FDA approves new indication for Byetta

FDA opens Cleveland BioLabs' IND for CBLB-502

Augment bone graft approved in Australia

Genticel completes recruitment in HPV vaccine trial

Syntaxin and Ipsen enter new global discovery and development collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...